Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS
Real world data
330
Clinical Sciences
OMOP CDM
610
Infectious and parasitic diseases
RC109-216
613
real world evidence
Article
OHDSI
SDG 3 - Good Health and Well-being
Clinical Research
open science
Clinical Epidemiology
Aetiology
Original Research
ohdsi
Prevention
name=Epidemiology
omop cdm
004
Descriptive epidemiology
3. Good health
real world data
Infectious Diseases
Good Health and Well Being
/dk/atira/pure/subjectarea/asjc/2700/2713
Public Health and Health Services
Real world evidence
Open science
descriptive epidemiology
2.4 Surveillance and distribution
DOI:
10.2147/clep.s323292
Publication Date:
2022-03-21T16:00:13Z
AUTHORS (75)
ABSTRACT
Abstract Background: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response [1,2]. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) [3] Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.Methods: We conducted a descriptive cohort study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub [4]. Findings: We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19, and 113,627 hospitalized with COVID-19 requiring intensive services. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts, and are available in an interactive website: https://data.ohdsi.org/Covid19CharacterizationCharybdis/. Interpretation: CHARYBDIS findings provide benchmarks that contribute to our understanding of COVID-19 progression, management and evolution over time. This can enable timely assessment of real-world outcomes of preventative and therapeutic options as they are introduced in clinical practice.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....